BrainSpec, Inc

BrainSpec, Inc develops a cloud-based software platform for Magnetic Resonance Spectroscopy (MRS) analysis. The platform provides non-invasive 'virtual biopsy' capability by measuring brain metabolite concentrations at precision levels 10,000 times lower than conventional MRI. BrainSpec Core™ combines a linear combinations model post-processing backend with a user-friendly web interface for clinicians and researchers. The platform supports cross-vendor MRI compatibility, enables precision metabolite measurement, and provides automated reporting with cloud-based processing to ensure access to cutting-edge analytical algorithms. Applications include assessment of brain tumors, Alzheimer's disease, Multiple Sclerosis, and other neurological conditions. The company has developed proprietary reference databases of normal and diseased brain chemistry to streamline MRS interpretation to clinical utility standards comparable to routine blood testing. The platform is currently in the pre-market stage with FDA clearance pending. The company is accepting a limited number of pilot research sites. Over 28,000 publications document clinical applications of MRS technology.